ESC 365 - Type of oral anticoagulants and outcomes after transcatheter aortic valve implantation

ESC Premium Access

Type of oral anticoagulants and outcomes after transcatheter aortic valve implantation

Session: Maintenance of anti-thrombotic therapy after TAVI

Topic: Pharmacotherapy

Speaker: Doctor D. Jochheim (Hattingen, DE)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor David Jochheim

MVZ Jochheim Medizin, Hattingen (Germany)

3 presentations

0 follower

4 more presentations in this session

TAVI thrombosis - Current knowledge

Speaker: Professor A. Finkelstein (Tel-Aviv, IL)

Continued vs. interrupted oral anticoagulation in patients with atrial fibrillation undergoing transfemoral transcatheter aortiv valve implantation

Speaker: Doctor N. Mangner (Dresden, DE)

Comparison of safety and benefits between single vs. dual antiplatelet therapy in patients undergoing transcatheter bioprosthetic aortic valve replacement: a meta-analysis

Speaker: Doctor S. Javed (The Bronx, US)

Anti-thrombotic therapy after TAVI - State of the art

Speaker: Professor R. Kornowski (Petah Tikva, IL)

Access the full session

Maintenance of anti-thrombotic therapy after TAVI

Speakers: Doctor D. Jochheim, Professor A. Finkelstein, Doctor N. Mangner, Doctor S. Javed, Professor R. Kornowski

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources